Table 2.
Treatment and toxicity.
| Characteristics | N (%) |
|---|---|
| Previous lines of systemic therapy: | |
| 0 | 3 (30) |
| 1 | 5 (70) |
| 2 | 2 (20) |
| Previous chemotherapy: | |
| IVADo/IVA | 4 (60) |
| VAC/IE | 2 (20) |
| EPI/IFOS | 1 (20) |
| Median of number of cycles (range) of BOMP-EPI | 2.5 (1–8) |
| Toxicity: | |
| • Hematologic: | |
| Grade 3-4 neutropenia | 7 (70) |
| Neutropenic fever | 2 (20) |
| G3-4 Anemia | 2 (20) |
| G3-4 thrombocytopenia | 1 (10) |
| • Non-hematologic: | |
| Grade 2 neuropathy | 1 (10) |
| Grade 2 hearing impairment | 1 (10) |
| Grade 3 mucositis | 1 (10) |
| • Toxic deaths | 0 |
IVADo—ifosfamide, vincristine, actinomycin and doxorubicin; IVA—ifosfamide, vincristine, actinomycin; VAC—vincristine, doxorubicin and cyclophosphamide; IE—ifosfamide and etoposide; EPI/IFOS—epirubicin and ifosfamide; BOMP-EPI—bleomycin, vincristine, methotrexate and cisplatin plus /etoposide, cisplatin and ifosfamide.